We have all watched in horror, the pandemic outbreak in India and have felt the need to do something. Well someone has! Merck announced that the company has entered into non-exclusive, voluntary licensing agreements for molnupiravir with five established Indian generics manufacturers. Molnupiravir is an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19.

“The scale of human suffering in India at this moment is devastating, and it is clear that more must be done to help alleviate it. These agreements, toward which we have been working as we have been studying molnupiravir, will help to accelerate access to molnupiravir in India and around the world”, said Kenneth C. Frazier, chairman, and CEO, Merck. “We remain committed to aiding in the global response that will bring relief to the people of India and, ultimately, bring an end to the pandemic.

Merck News Release April 27, 2021

Thank you, Merck and all of your shareholders for your generous support of the people in India. As we continue to follow the events in India and think “by the grace of God go I”, please keep these people in your thoughts and prayers. Stay well, mask up indoors and stay tuned!